(3E)-3-[2-(3-Chlorophenyl)hydrazin-1-ylidene]-1-[(3,4-dichlorophenyl)methyl]-2,3-dihydro-1H-indol-2-one

Catalog No. :
ACETLW874
CAS No. :
303985-20-8
Molecular Formula :
C21H14Cl3N3O
Molecular Weight :
430.72

IUPAC Name:(E)-3-(2-(3-chlorophenyl)hydrazineylidene)-1-(3,4-dichlorobenzyl)indolin-2-one

(3E)-3-[2-(3-Chlorophenyl)hydrazin-1-ylidene]-1-[(3,4-dichlorophenyl)methyl]-2,3-dihydro-1H-indol-2-one structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g90%$316.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(3E)-3-[2-(3-Chlorophenyl)hydrazin-1-ylidene]-1-[(3,4-dichlorophenyl)methyl]-2,3-dihydro-1H-indol-2-one
IUPAC Name(E)-3-(2-(3-chlorophenyl)hydrazineylidene)-1-(3,4-dichlorobenzyl)indolin-2-one
Molecular FormulaC21H14Cl3N3O
Molecular Weight430.72
SMILESO=C1/C(=N/NC2=CC=CC(Cl)=C2)C2=C(C=CC=C2)N1CC1=CC=C(Cl)C(Cl)=C1
InChI KeyGAQPMPZOZPUXJZ-LHLOQNFPSA-N
Synonym1-(3,4-DICHLOROBENZYL)-1H-INDOLE-2,3-DIONE 3-[N-(3-CHLOROPHENYL)HYDRAZONE];(3E)-3-[2-(3-chlorophenyl)hydrazin-1-ylidene]-1-[(3,4-dichlorophenyl)methyl]-2,3-dihydro-1H-indol-2-one;1H-Indole-2,3-dione, 1-[(3,4-dichlorophenyl)methyl]-, 3-[2-(3-chlorophenyl)hydrazone]
CAS No.303985-20-8

Synthetic Route by SureRoute

1. ACETLW874 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACZSOK389 route compound structure diagram
    ACZSOK3892312-23-4 In Stock
  2. Plus
  3. ACIVNU371 route compound structure diagram
    ACIVNU37179183-19-0 In Stock
  4. Then
  5. ACETLW874 route product structure diagram
    ACETLW874303985-20-8
Inquiry

2. ACETLW874 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACETLW874 route product structure diagram
    ACETLW874303985-20-8
Inquiry

Comments (0)